Gusky Adam Samuel

Director Adam Samuel Gusky purchases 1,030 shares of RAND at $14.80 blended average as stock down -48.9% from 52-week high.

Adam Samuel Gusky, a Director at RAND Capital, executed 12 separate purchases totaling 1,030 shares for $15,246.55 on September 15, 2025, at prices ranging from $14.55 to $15.00 with a blended average of $14.80. This represents a 3.2% increase to his holdings, raising his position from 32,516 to 33,546 shares. The purchases occurred as RAND's stock trades at $14.56, down -48.9% from its 52-week high of $28.50 and off -4.3% over the past 30 days. His same-ticker history shows 4 of 5 prior purchases at RAND were well-timed at the 90-day mark, with two late-2024 buys posting 90-day returns near +70%; however, his two most recent purchases at this ticker in May 2025 posted modest negative 90-day returns (-0.6% and -0.1%). Against the backdrop of negative net income of $-7,736,154.00 and a deteriorating price trend, the sustained accumulation warrants observation of whether current fundamentals support the prior buy-pattern success.

Director Gusky buys 212 shares at $15.76 avg; adds 0.7% to 32.5K-share position; RAND down 42.0% from 52-week high.

Adam Samuel Gusky, a Director at RAND CAPITAL CORP, made 2 separate purchases totaling 212 shares for $3,342.00 between May 27–28, 2025, at an average price of $15.76. The stock is currently trading at $16.53, down 42.0% from its 52-week high of $28.50 and down 26.4% over the past 90 days. Gusky's same-ticker purchase history at RAND shows a strong pattern: 4 of his 5 prior buys at this ticker generated 90-day returns ranging from +69.0% to +73.3%, suggesting he has demonstrated timing skill in identifying recovery opportunities at this specific company. His cross-ticker track record of 20 prior buys shows a 65.00% 90-day win rate with an average 90-day return of +24.6%, indicating consistent buy-side accuracy across portfolios. The current purchase, while modest in size (0.7% increase to his 32.5K-share holding), occurs at a historically depressed valuation relative to the 52-week range and follows a period of significant price erosion, making this transaction a data point worth tracking for early signals of insider perspective on recovery catalysts.

Director Gusky buys 10,000 ABL shares (3 trades, $7.70–$7.85) for $77,600.00; holdings rise 20.4% to 59,085 shares

Adam Samuel Gusky, Director of Abacus Life, Inc., executed 3 separate purchases totaling 10,000 shares for $77,600.00 between December 13 and December 16, 2024, at prices ranging from $7.70 to $7.85 per share. This represents a 20.4% increase in his shareholding from 49,085 to 59,085 shares. His cross-ticker track record shows 19 prior open-market buys with an 83.33% 90-day win rate and average 90-day returns of +19.1%, while his prior trades at ABL specifically—including two buys in November 2023—delivered strong 90-day returns of +104.5% and +99.6%. The current stock price of $7.86 sits 37.0% below the 52-week high of $12.47 and has declined 20.4% over the past 90 days, placing the purchase window at a depressed absolute level within the recent price range. The company is growing revenue at +48.5% year-over-year but remains unprofitable at the latest quarter (-$5.1M net income on $28.1M revenue), suggesting the director's accumulation occurs amid both growth momentum and ongoing operational challenges.

Director Gusky purchases 8,126 shares in 2 tranches at $7.93–$7.94 for $64,474.80; holds 49,085 post-trade after +19.8% increase.

Director Adam Samuel Gusky executed 2 separate purchases totaling 8,126 shares for $64,474.80, increasing his holdings by 19.8% from 40,959 to 49,085 shares. His cross-ticker track record shows 17 prior buys with an 83.33% 90-day win rate and avg 90d return of +19.1%, though his same-ticker history at ABL is more limited: his last two buys (2023-11-16 and 2023-11-17) delivered +99.6% and +104.5% 90-day returns respectively. The current stock price of $8.03 sits 35.6% below the 52-week high of $12.47 and has declined 11.0% over 30 days and 18.4% over 90 days, positioning the purchases near recent lows. Abacus Life reports strong annual revenue growth of 48.5%, though the latest quarter shows a net loss of $5,125,055.00 on revenue of $28,148,491.00, and the P/E of 47.24 reflects a richly-valued profile. The accumulation pattern and scale suggest continued confidence in the equity, though the fundamental losses and valuation metrics present counterbalancing considerations.

Director Gusky bought 18,241 shares of ABL at $7.54 (+80.3% to holdings); prior 2 ABL buys returned +33.7% and +30.6% in 30 days.

Director Adam Samuel Gusky purchased 18,241 shares at $7.54 on 2024-11-22, expanding his stake from 22,718 to 40,959 shares (+80.3%). This mirrors his prior transaction pattern at ABL: his two previous open-market purchases (2023-11-16 and 2023-11-17) each posted positive 90-day returns of +99.6% and +104.5%, indicating a track record of well-timed accumulation at this ticker. His cross-ticker open-market history spans 16 prior buys with an 83.33% 90-day win rate and average 90d return of +19.1%, reinforcing consistent execution discipline. The current environment presents pressure: stock is down 10.2% over 30 days, down 19.2% over 90 days, and trading 35.2% below its 52-week high of $12.47. Despite the depressed price, Gusky's decision to add shares at $7.54 (now trading at $8.08) occurs against a backdrop of profitable revenue growth (+48.5% year-over-year) offset by a $-5.1M net loss in the latest quarter. The timing and magnitude of his purchase—combined with his historical precision at this ticker—warrant close attention to whether this reflects informed confidence in a turnaround or anticipation of near-term catalysts.

Director Gusky purchases 375 shares at $16.11 avg; 28.1K holding. 3 of 5 prior RAND buys well-timed at 90d.

Gusky Adam Samuel, a Director of RAND, executed 4 separate purchases totaling 375 shares for $6,041.25 across November 20–21, 2024, at a blended average price of $16.11. His post-transaction holdings stand at 28.1K shares. At the time of filing, the stock traded at $16.33, only 1.4% above his entry price, and sits 15.0% below its 52-week high of $19.20. His prior transaction history at RAND shows 5 documented buys since June 2023; 3 of those 5 buys proved well-timed at the 90-day mark (meaning the stock rose after purchase). This pattern of selective timing success on the same ticker is noteworthy, though his 30-day returns on those prior RAND buys averaged modest gains, and recent price action shows the stock down 11.9% over 90 days. The company's P/E of 3.28 and net income of $2.6M on a $42.1M market cap suggest a deeply valued small-cap position, which may explain the volatility and the director's continued accumulation.